What a fantastic trial!
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - The Lancet www.thelancet.com/journals/lan...
Semaglutide showed robust therapeutic effects in treatment-seeking participants with
obesity and alcohol use disorder and this trial supports previous preclinical and
clinical findings suggesting GLP-...
